Phosphatidylinositol 4,5-bisphosphate alters pharmacological selectivity for epilepsy-causing KCNQ potassium channels

Proceedings of the National Academy of Sciences of the United States of America

Volumn 110, Issue 21, 2013, Pages 8726-8731

  Zhou, Pingzheng ^a   Yu, Haibo ^b   Gu, Min ^a   Nan, Fa Jun ^a   Gao, Zhaobing ^a   Li, Min ^a,b  

^a SHANGHAI INSTITUTE OF MATERIA MEDICA   (China)

^b JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Cardiac arrhythmias; Chemical probe; Gating modifier; Hyperexcitability; Pain

Indexed keywords

MUSCARINIC RECEPTOR; PHOSPHATASE; PHOSPHATIDYLINOSITOL 4,5 BISPHOSPHATE; POTASSIUM CHANNEL KCNQ2; POTASSIUM CHANNEL KCNQ3; PYRITHIONE ZINC; RETIGABINE;

ANIMAL CELL; ARTICLE; CONTROLLED STUDY; DRUG SELECTIVITY; DRUG SENSITIVITY; EPILEPSY; NONHUMAN; PLASTICITY; PRIORITY JOURNAL;

CARDIAC ARRHYTHMIAS; CHEMICAL PROBE; GATING MODIFIER; HYPEREXCITABILITY; PAIN;

ANIMALS; ANTICONVULSANTS; CARBAMATES; CHO CELLS; CRICETINAE; CRICETULUS; EPILEPSY; KCNQ2 POTASSIUM CHANNEL; KCNQ3 POTASSIUM CHANNEL; KERATOLYTIC AGENTS; MICE; MUTATION; NERVE TISSUE PROTEINS; NEURONS; ORGANOMETALLIC COMPOUNDS; PHENYLENEDIAMINES; PHOSPHATIDYLINOSITOL 4,5-DIPHOSPHATE; PYRIDINES; SIGNAL TRANSDUCTION;

EID: 84878123925     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1302167110     Document Type: Article

References (51)

1. Delmas P, Brown DA (2005) Pathways modulating neural KCNQ/M (Kv7) potassium channels. Nat Rev Neurosci 6(11): 850-862.
2. Suh BC, Inoue T, Meyer T, Hille B (2006) Rapid chemically induced changes of PtdIns (4,5)P2 gate KCNQ ion channels. Science 314(5804): 1454-1457.
3. Brown DA, Adams PR (1980) Muscarinic suppression of a novel voltage-sensitive K+ current in a vertebrate neurone. Nature 283(5748): 673-676.
4. Brown DA, Passmore GM (2009) Neural KCNQ (Kv7) channels. Br J Pharmacol 156(8): 1185-1195.
5. Miceli F, Soldovieri MV, Martire M, Taglialatela M (2008) Molecular pharmacology and therapeutic potential of neuronalKv7-modulating drugs. CurrOpin Pharmacol 8(1): 65-74.
6. Robbins J (2001) KCNQ potassium channels: Physiology, pathophysiology, and pharmacology. Pharmacol Ther 90(1): 1-19.
7. Greenwood IA, Ohya S (2009) New tricks for old dogs: KCNQ expression and role in smooth muscle. Br J Pharmacol 156(8): 1196-1203.
8. Neyroud N, et al. (1997) A novelmutation in the potassiumchannel gene KVLQT1 causes the Jervell and Lange-Nielsen cardioauditory syndrome. Nat Genet 15(2): 186-189.
9. Sanguinetti MC, Zou A (1997) Molecular physiology of cardiac delayed rectifier K+ channels. Heart Vessels 12(Suppl 12): 170-172.
10. Yamada M, Welty TE (2012) Ezogabine: An evaluation of its efficacy and safety as adjunctive therapy for partial-onset seizures in adults. Ann Pharmacother 46(10): 1358-1367.
11. Orhan G, Wuttke TV, Nies AT, Schwab M, Lerche H (2012) Retigabine/Ezogabine, a KCNQ/K(V)7 channel opener: Pharmacological and clinical data. Expert Opin Pharmacother 13(12): 1807-1816.
12. Brodie MJ, et al. RESTORE 2 Study Group (2010) Efficacy and safety of adjunctive ezogabine (retigabine) in refractory partial epilepsy. Neurology 75(20): 1817-1824.
13. Gunthorpe MJ, Large CH, Sankar R (2012) The mechanism of action of retigabine (ezogabine), a first-in-class K+ channel opener for the treatment of epilepsy. Epilepsia 53(3): 412-424.
14. Schenzer A, et al. (2005) Molecular determinants of KCNQ (Kv7) K+ channel sensitivity to the anticonvulsant retigabine. J Neurosci 25(20): 5051-5060.
15. Wuttke TV, Seebohm G, Bail S, Maljevic S, Lerche H (2005) The new anticonvulsant retigabine favors voltage-dependent opening of the Kv7.2 (KCNQ2) channel by binding to its activation gate. Mol Pharmacol 67(4): 1009-1017.
16. Lange W, et al. (2009) Refinement of the binding site and mode of action of the anticonvulsant Retigabine on KCNQ K+ channels. Mol Pharmacol 75(2): 272-280.
17. Xiong Q, Sun H, Li M (2007) Zinc pyrithione-mediated activation of voltage-gated KCNQ potassium channels rescues epileptogenic mutants. Nat Chem Biol 3(5): 287-296.
18. Xiong Q, Sun H, Zhang Y, Nan F, Li M (2008) Combinatorial augmentation of voltagegated KCNQ potassium channels by chemical openers. Proc Natl Acad Sci USA 105(8): 3128-3133.
19. Miceli F, et al. (2011) The voltage-sensing domain of K(v)7.2 channels as a molecular target for epilepsy-causing mutations and anticonvulsants. Front Pharmacol 2:2.
20. Gao Z, et al. (2010) Isoform-specific prolongation of Kv7 (KCNQ) potassium channel opening mediated by new molecular determinants for drug-channel interactions. J Biol Chem 285(36): 28322-28332.
21. Padilla K, Wickenden AD, Gerlach AC, McCormack K (2009) The KCNQ2/3 selective channel opener ICA-27243 binds to a novel voltage-sensor domain site. Neurosci Lett 465(2): 138-142.
22. Wickenden AD, et al. (2008) N-(6-chloro-pyridin-3-yl)-3,4-difluoro- benzamide (ICA- 27243): A novel, selective KCNQ2/Q3 potassium channel activator. Mol Pharmacol 73(3): 977-986.
23. Peretz A, et al. (2010) Targeting the voltage sensor of Kv7.2 voltage-gated K+ channels with a new gating-modifier. Proc Natl Acad Sci USA 107(35): 15637-15642.
24. Zhang H, et al. (2003) PIP(2) activates KCNQ channels, and its hydrolysis underlies receptor-mediated inhibition of M currents. Neuron 37(6): 963-975.
25. Li Y, Gamper N, Hilgemann DW, Shapiro MS (2005) Regulation of Kv7 (KCNQ) K+ channel open probability by phosphatidylinositol 4,5-bisphosphate. J Neurosci 25(43): 9825-9835.
26. Suh BC, Hille B (2007) Regulation of KCNQ channels by manipulation of phosphoinositides. J Physiol 582(Pt 3): 911-916.
27. Main MJ, et al. (2000) Modulation of KCNQ2/3 potassium channels by the novel anticonvulsant retigabine. Mol Pharmacol 58(2): 253-262.
28. Tatulian L, Delmas P, Abogadie FC, Brown DA (2001) Activation of expressed KCNQ potassium currents and native neuronal M-type potassium currents by the anti-convulsant drug retigabine. J Neurosci 21(15): 5535-5545.
29. Lerche C, et al. (2000) Molecular cloning and functional expression of KCNQ5, a potassium channel subunit that may contribute to neuronal M-current diversity. J Biol Chem 275(29): 22395-22400.
30. Wickenden AD, Yu W, Zou A, Jegla T, Wagoner PK (2000) Retigabine, a novel anticonvulsant, enhances activation of KCNQ2/Q3 potassium channels. Mol Pharmacol 58(3): 591-600.
31. Suh BC, Hille B (2008) PIP2 is a necessary cofactor for ion channel function: How and why? Annu Rev Biophys 37: 175-195.
32. Várnai P, Balla T (1998) Visualization of phosphoinositides that bind pleckstrin homology domains: Calcium- and agonist-induced dynamic changes and relationship to myo-[3H]inositol-labeled phosphoinositide pools. J Cell Biol 143(2): 501-510.
33. Etxeberria A, Santana-Castro I, Regalado MP, Aivar P, Villarroel A (2004) Three mechanisms underlie KCNQ2/3 heteromeric potassium M-channel potentiation. J Neurosci 24(41): 9146-9152.
34. Hernandez CC, Falkenburger B, Shapiro MS (2009) Affinity for phosphatidylinositol 4,5-bisphosphate determines muscarinic agonist sensitivity of Kv7 K+ channels. J Gen Physiol 134(5): 437-448.
35. Hossain MI, et al. (2008) Enzyme domain affects the movement of the voltage sensor in ascidian and zebrafish voltage-sensing phosphatases. J Biol Chem 283(26): 18248-18259.
36. Hernandez CC, Zaika O, Shapiro MS (2008) A carboxy-terminal inter-helix linker as the site of phosphatidylinositol 4,5-bisphosphate action on Kv7 (M-type) K+ channels. J Gen Physiol 132(3): 361-381.
37. Xiong Q, Gao Z, Wang W, Li M (2008) Activation of Kv7 (KCNQ) voltage-gated potassium channels by synthetic compounds. Trends Pharmacol Sci 29(2): 99-107.
38. Börjesson SI, Elinder F (2011) An electrostatic potassium channel opener targeting the final voltage sensor transition. J Gen Physiol 137(6): 563-577.
39. Rodriguez-Menchaca AA, et al. (2012) PIP2 controls voltage-sensor movement and pore opening of Kv channels through the S4-S5 linker. Proc Natl Acad Sci USA 109(36): E2399-E2408.
40. Hilgemann DW, Ball R (1996) Regulation of cardiac Na+,Ca2+ exchange and KATP potassium channels by PIP2. Science 273(5277): 956-959.
41. Catimel B, et al. (2008) The PI(3,5)P2 and PI(4,5)P2 interactomes. J Proteome Res 7(12): 5295-5313.
42. Kim AY, et al. (2008) Pirt, a phosphoinositide-binding protein, functions as a regulatory subunit of TRPV1. Cell 133(3): 475-485.
43. Linley JE, Pettinger L, Huang D, Gamper N (2012) M channel enhancers and physiological M channel block. J Physiol 590(Pt 4): 793-807.
44. Hernandez CC, Zaika O, Tolstykh GP, Shapiro MS (2008) Regulation of neural KCNQ channels: Signalling pathways, structural motifs and functional implications. J Physiol 586(7): 1811-1821.
45. Wua YJ, Dworetzky SI (2005) Recent developments on KCNQ potassium channel openers. Curr Med Chem 12(4): 453-460.
46. Wulff H, Castle NA, Pardo LA (2009) Voltage-gated potassium channels as therapeutic targets. Nat Rev Drug Discov 8(12): 982-1001.
47. Ahlemeyer B, Baumgart-Vogt E (2005) Optimized protocols for the simultaneous preparation of primary neuronal cultures of the neocortex, hippocampus and cerebellum from individual newborn (P0.5) C57Bl/6J mice. J Neurosci Methods 149(2): 110-120.
48. Liu XH, Lü GW, Cui ZJ (2002) Calcium oscillations in freshly isolated neonatal rat cortical neurons. Acta Pharmacol Sin 23(7): 577-581.
49. Zhang SL, et al. (2001) Effect of dl-praeruptorin A on ATP sensitive potassium channels in human cortical neurons. Acta Pharmacol Sin 22(9): 813-816.
50. Zhang W, Jin HW, Wang XL (2004) Effects of presenilins and beta-amyloid precursor protein on delayed rectifier potassium channels in cultured rat hippocampal neurons. Acta Pharmacol Sin 25(2): 181-185.
51. Logothetis DE, Petrou VI, Adney SK, Mahajan R (2010) Channelopathies linked to plasma membrane phosphoinositides. Pflugers Arch 460(2): 321-341.